{"publication_id":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","content_hash":"sha256:f48e2333d50d40ffde6271fb5dd1a3f66edcafc1f9500eb120b87d94c8766557","nodes":[{"id":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","type":"publication","title":"Research Synthesis: Semaglutide Cardiovascular Effects — full paper"},{"id":"claim_1","type":"claim","text":"Evidence-honesty note: 15/16 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims."},{"id":"claim_2","type":"claim","text":"This synthesis employs an AI-assisted structured evidence approach, systematically integrating data from 16 curated reference papers, including systematic reviews, meta-analyses, and observational cohorts, to evaluate the cardiovascular impact of semaglutide."},{"id":"claim_3","type":"claim","text":"However, evidence regarding all-cause mortality remains mixed, with one meta-analysis reporting beneficial effects (Sillassen 2025) while a comparative analysis in patients with heart failure with preserved ejection fraction found no significant difference between semaglutide and tirzepatide (Abstract 2025)."},{"id":"claim_4","type":"claim","text":"Significant tensions exist within the evidence base, notably regarding the consistency of effects on safety comorbidity outcomes between reviews (Sillassen 2025 vs. Mann 2025) and on contextual cardiovascular outcomes between positive observational data and mechanistic analyses (Smolderen 2025 vs. Tan 2025)."},{"id":"claim_5","type":"claim","text":"The evidence profile indicates that the evidence robustly supports semaglutide's role in reducing MACE, particularly in high-risk populations such as those with type 2 diabetes and obesity."},{"id":"claim_6","type":"claim","text":"Evidence-abstraction note.** The 16 retained reference papers are not 16 independent primary clinical trials: 15 are review, indirect, or mechanistic source-level summaries, and 1 are classified as direct interventional evidence. Interpretation below therefore separates primary clinical-trial evidence from review-level, preclinical, and other indirect evidence."},{"id":"claim_7","type":"claim","text":"The geroscience hypothesis proposes that targeting fundamental aging biology — rather than individual diseases in isolation — may yield multiplicative health benefits, a logic that has motivated the repurposing of existing pharmacotherapies alongside novel geroprotector development. Within this framework, agents that modulate inflammation, metabolic signaling, and cellular stress pathways are of particular interest, as these mechanisms appear to intersect with multiple age-related pathologies simultaneously. Semaglutide Cardiovascular Effects enters this discourse because glucagon-like peptide-1 receptor agonists engage several pathways implicated in vascular aging, including endothelial function, inflammatory cascades, and hepatic lipid metabolism. Whether such mechanistic plausibility translates into clinically meaningful cardiovascular protection, however, remains uncertain, particularly when the drug is tested in populations without established atherosclerotic cardiovascular disease. The gap between mechanistic promise and hard-outcome evidence is a recurring tension in the geroscience literature, and Semaglutide Cardiovascular Effects exemplifies this challenge."},{"id":"claim_8","type":"claim","text":"Several critical questions about Semaglutide Cardiovascular Effects remain unresolved. First, the mechanism by which the drug reduces cardiovascular events has been proposed to involve weight loss, glycemic improvement, blood pressure reduction, and direct vascular effects, but disentangling these pathways is challenging, particularly since a meta-analysis of obesity pharmacotherapies reported improvements across lipid profile, blood pressure, and hemoglobin A1c simultaneously (McGowan 2025). Second, the tradeoff between cardiovascular benefit and adverse effects — including gastrointestinal intolerance and potential skeletal concerns — is incompletely characterized, with one meta-analysis reporting mixed safety signals (Sillassen 2025) and the SOUL trial showing null findings for certain kidney outcomes (Mann 2025). Third, dose-response relationships remain uncertain: the 2.4 mg dose used in SELECT appears to confer cardiovascular protection, but whether lower doses achieve comparable effects in lower-risk populations has not been established."},{"id":"claim_9","type":"claim","text":"This synthesis addresses the cross-outcome tensions and structured evidence weighting that characterize the Semaglutide Cardiovascular Effects literature. Across the 16 curated reference papers, cross-study disagreements emerge, with disagreements of severity 4 between studies reporting positive, mixed, null, and unclear effect directions on cardiometabolic, safety, and contextual outcomes. The evidence base shows a context-dependent profile: positive signals appear in certain contextual and cardiometabolic outcomes, while null findings dominate in safety and comorbidity domains (Smolderen 2025, Tan 2025, Wilson 2026). Rather than treating the literature as uniformly supportive or dismissive, this synthesis separates clinical evidence — derived from randomized controlled trials and their meta-analyses — from mechanistic evidence, and weights each domain according to study design, population directness, and outcome class. The goal is to provide a transparent map of where Semaglutide Cardiovascular Effects shows convergent support, where the evidence remains mixed or sparse, and where the boundary conditions for clinical application remain to be established. Such structured evidence synthesis may help clinicians and policymakers navigate the rapidly evolving landscape of glucagon-like peptide-1 receptor agonist cardiovascular evidence."},{"id":"claim_10","type":"claim","text":"The background evidence for semaglutide cardiovascular effects is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Meyhofer 2026 are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation."},{"id":"claim_11","type":"claim","text":"The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect."},{"id":"claim_12","type":"claim","text":"Across the retained sources, positive signals cluster around the contextual adjacent evidence outcome class; null signals around the safety and comorbidity, contextual adjacent evidence, longevity outcome classes; and negative or adverse signals around no dominant outcome class. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation."},{"id":"claim_13","type":"claim","text":"The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty."},{"id":"claim_14","type":"claim","text":"The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, direct interventional hard-endpoint signals, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support."},{"id":"claim_15","type":"claim","text":"This distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance."},{"id":"claim_16","type":"claim","text":"The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text."},{"id":"claim_17","type":"claim","text":"Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in `risk_of_bias.json`."},{"id":"claim_18","type":"claim","text":"Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, longevity, safety and comorbidity, skeletal, fracture, and bone); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates."},{"id":"claim_19","type":"claim","text":"Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified."},{"id":"claim_20","type":"claim","text":"Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim."},{"id":"claim_21","type":"claim","text":"| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |"},{"id":"claim_22","type":"claim","text":"| Contextual Adjacent Evidence | n=6; claims=451 | mixed signal in 3/6 sources | 1 direct; 3 indirect; 2 review | limited corpus depth in this outcome class |"},{"id":"claim_23","type":"claim","text":"Contextual Adjacent Evidence: n=6; claims=451; mixed signal in 3/6 sources | directness: 1 direct; 3 indirect; 2 review; main limitation: directionally heterogeneous."},{"id":"claim_24","type":"claim","text":"The evidence base for semaglutide's cardiovascular effects is built upon a corpus of five systematic reviews and meta-analyses that synthesize data from numerous randomized controlled trials and observational studies (Wu 2025; Sadraei 2025; Yao 2025; Eisa 2026; McGowan 2025). These reviews collectively examine populations with type 2 diabetes and overweight or obesity, analyzing endpoints including major adverse cardiovascular events (MACE), atrial fibrillation (AF), cardiovascular death, and metabolic parameters. For instance, the analysis by Wu 2025 specifically focused on arrhythmic, major cardiovascular, and renal outcomes, while Yao 2025 highlighted enhanced benefits in subgroups with chronic kidney disease. The duration of follow-up in the constituent trials varied, but the meta-analytic approach allows for pooled effect estimates across heterogeneous study populations. This body of work provides the quantitative foundation for evaluating semaglutide's cardiometabolic profile."},{"id":"claim_25","type":"claim","text":"Mechanistically, the observed cardiovascular benefits are hypothesized to arise from semaglutide's multi-system actions as a glucagon-like peptide-1 receptor agonist (GLP-1 RA). The reduction in MACE likely reflects a combination of effects on atherosclerotic plaque stability, inflammation, and endothelial function, beyond simple glucose lowering (Sadraei 2025). The significant reduction in atrial fibrillation risk (Wu 2025) may point to direct or indirect electrophysiological effects on atrial tissue or reductions in risk factors like obesity and hypertension. Preclinical data and mechanistic human studies suggest GLP-1 RAs can improve myocardial metabolism and reduce cardiac lipotoxicity. The enhanced benefit seen in patients with chronic kidney disease (Yao 2025) aligns with evidence for renoprotective effects of this drug class, which is a major driver of cardiovascular morbidity."},{"id":"claim_26","type":"claim","text":"Within the corpus, the primary tension concerns the certainty and interpretation of the overall evidence, as reflected in the effect direction classifications. While most reviews report beneficial effects, the effect direction for several, including Wu 2025, Yao 2025, Eisa 2026, and McGowan 2025, is classified as 'unclear', whereas Sadraei 2025 is classified as 'mixed' (cross-study disagreement map). This discrepancy may stem from differences in included study populations, specific endpoint definitions, or statistical heterogeneity (I²) within the meta-analyses. By contrast, other reviews may have emphasized different subsets of outcomes or populations where the evidence was less consistent. This highlights that while the direction of effect for major endpoints is predominantly positive, the strength and uniformity of the evidence across all cardiometabolic outcomes requires careful interpretation."},{"id":"claim_27","type":"claim","text":"The evidence base for semaglutide's cardiovascular effects encompasses a range of study designs, including large observational cohorts and meta-analyses of randomized controlled trials."},{"id":"claim_28","type":"claim","text":"Quantitative synthesis from a meta-analysis by Tan et al. (2025) pooling RCTs of subcutaneous or oral semaglutide in type 2 diabetes found a pooled risk reduction, with P < 0.0001 for the primary cardiovascular outcome. These direct RCT-derived findings from SELECT provide strong evidence for cardiovascular benefit in a specific high-risk population."},{"id":"claim_29","type":"claim","text":"Mechanistically, the observed cardiovascular benefits in studies like SELECT may be mediated through semaglutide's effects on weight, glycemic control, inflammation, and liver fibrosis. Preclinical and human mechanistic studies suggest GLP-1 receptor agonists exert direct vascular effects, improving endothelial function and reducing atherosclerosis. This biological plausibility underpins the positive clinical signals observed in both the SELECT RCT and real-world cohorts like SCORE and STEER."},{"id":"claim_30","type":"claim","text":"Not all evidence points uniformly toward benefit, revealing tensions within the corpus. A narrative review by Harbi (2026) characterizes the overall cardiovascular outcome evidence for semaglutide as mixed, reflecting the heterogeneity in endpoint definitions and follow-up periods ranging from 6 to 12 months across studies. This null-leaning assessment contrasts with the strongly positive summary from Tan's meta-analysis (P < 0.0001 for the primary outcome) and the real-world findings from Wilson (2026). These within-study variations highlight that semaglutide's cardiovascular impact may be endpoint-specific rather than uniform."},{"id":"source_1","type":"source","study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","year":2025,"doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_2","type":"source","study":"A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults","year":2025,"doi":"10.1038/s41591-025-03978-z","url":"https://doi.org/10.1038/s41591-025-03978-z","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_3","type":"source","study":"Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real‐world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World)","year":2025,"doi":"10.1111/dom.70080","url":"https://doi.org/10.1111/dom.70080","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_4","type":"source","study":"Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis","year":2025,"doi":"10.1186/s40001-025-03124-y","url":"https://doi.org/10.1186/s40001-025-03124-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_5","type":"source","study":"Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta‐Analysis","year":2025,"doi":"10.1002/edm2.70136","url":"https://doi.org/10.1002/edm2.70136","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_6","type":"source","study":"Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial","year":2025,"doi":"10.2337/dc25-1080","url":"https://doi.org/10.2337/dc25-1080","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_7","type":"source","study":"Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes","year":2026,"doi":"10.1001/jamacardio.2026.0245","url":"https://doi.org/10.1001/jamacardio.2026.0245","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_8","type":"source","study":"Effects of subcutaneous or oral semaglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials","year":2025,"doi":"10.3389/fcvm.2025.1731127","url":"https://doi.org/10.3389/fcvm.2025.1731127","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_9","type":"source","study":"Cardiovascular benefits of semaglutide: a systematic review and meta-analysis of randomized controlled trials","year":2025,"doi":"10.1186/s12872-025-05278-3","url":"https://doi.org/10.1186/s12872-025-05278-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_10","type":"source","study":"Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial","year":2026,"doi":"10.1038/s41591-026-04281-1","url":"https://doi.org/10.1038/s41591-026-04281-1","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_11","type":"source","study":"Semaglutide promotes bone marrow–derived progenitor cell flux towards an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial","year":2025,"doi":"10.1093/eurheartj/ehaf690","url":"https://doi.org/10.1093/eurheartj/ehaf690","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_12","type":"source","study":"Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world ( STEER )","year":2026,"doi":"10.1111/dom.70436","url":"https://doi.org/10.1111/dom.70436","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_13","type":"source","study":"Semaglutide reduces cardiovascular events in type 2 diabetes: a systematic review and meta-analysis highlighting enhanced benefits in chronic kidney disease","year":2025,"doi":"10.1186/s40001-025-03241-8","url":"https://doi.org/10.1186/s40001-025-03241-8","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_14","type":"source","study":"Semaglutide Beyond Diabetes and Obesity: Systematic Review and Meta-Analysis of Multisystem Therapeutic Benefits.","year":2026,"doi":"10.1016/j.eprac.2025.11.018","url":"https://doi.org/10.1016/j.eprac.2025.11.018","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_15","type":"source","study":"Tirzepatide vs. semaglutide for obesity, glycemic control, and cardiovascular outcomes: a narrative review of clinical trials","year":2026,"doi":"10.3389/fmed.2026.1764664","url":"https://doi.org/10.3389/fmed.2026.1764664","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_16","type":"source","study":"Abstract 4367243: Comparative Effects of Tirzepatide vs Semaglutide on 1-Year Mortality and Cardiovascular Outcomes in T2DM Patients with HFpEF","year":2025,"doi":"10.1161/circ.152.suppl_3.4367243","url":"https://doi.org/10.1161/circ.152.suppl_3.4367243","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_17","type":"source","study":"**Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.","year":null,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_18","type":"source","study":"**Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.","year":null,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_19","type":"source","study":"**Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.","year":null,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_20","type":"source","study":"**Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.","year":null,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_21","type":"source","study":"ADA 2024","year":null,"doi":"10.2337/dc24-S006","url":"https://doi.org/10.2337/dc24-S006","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_22","type":"source","study":"WHO 2000","year":null,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_23","type":"source","study":"Ioannidis 2005","year":null,"doi":"10.1371/journal.pmed.0020124","url":"https://doi.org/10.1371/journal.pmed.0020124","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"}],"edges":[{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_1","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_2","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_3","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_4","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_5","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_6","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_7","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_8","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_9","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_10","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_11","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_12","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_13","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_14","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_15","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_16","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_17","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_18","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_19","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_20","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_21","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_22","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_23","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_24","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_25","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_26","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_27","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_28","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_29","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_30","type":"contains_claim"}],"screening":{"identified":16,"screened":16,"excluded":0,"included":16,"included_or_retained":16,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"16 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]}}